Wim Van Schooten PhD

Dr. van Schooten has over 20 years of biotechnology management experience, including research and development supervision, manufacturing and regulatory operations. Dr. van Schooten co-founded THP, Inc. with Dr. Buelow in 2000 and served as its Chief Executive Officer from 2002 until its sale to Roche Pharmaceuticals in March 2007. From 1993 to1999, he led the development of therapeutics for the treatment of prostate cancer and multiple myeloma at Dendreon. Dr. van Schooten also directed the quality and clinical research programs, leading to the approval of a device and Phase III studies in cancers. Dr. van Schooten studied Immunology at the University of Leiden and the Royal Tropical Institute in Amsterdam.